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CDC25AWnt signaling determines human stromal (mesenchymal) stem cell (hMSC) differentiation fate into the osteo-
blast or adipocyte lineage. microRNAs (miRNAs) are small RNA molecules of 21–25 nucleotides that regulate
many aspects of osteoblast biology. Thus, we examined miRNAs regulated by Wnt signaling in hMSC. We iden-
tiﬁed miRNA (miR)-141-3p as a Wnt target which in turn inhibited Wnt signaling. Moreover, miR-141-3p
inhibited hMSC proliferation by arresting cells at the G1 phase of the cell cycle. miR-141-3p inhibited osteoblast
differentiation of hMSC as evidenced by reduced alkaline phosphatase activity, gene expression and in vitromin-
eralized matrix formation. Bioinformatic studies, Western blot analysis and 3’UTR reporter assay demonstrated
that cell division cycle 25A (CDC25A) is a direct target of miR-141-3p. siRNA-mediated knock-down of
CDC25A inhibited hMSC proliferation and osteoblast differentiation. In summary, miR-141-3p acts as a negative
regulator of hMSC proliferation and osteoblast differentiation. TargetingmiR-141-3p could be used as an anabolic
therapy of low bone mass diseases, e.g. osteoporosis.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
microRNAs (miRNAs) are a large family of evolutionarily conserved,
small (approximately 22 nucleotides in length) and non-coding RNA
molecules [1,2]. To date, more than 1400 miRNAs have been identiﬁed
in human cells, and each is predicted to regulate several target genes
[3,4]. miRNAs regulate gene expression either at the posttranscriptional
level by binding to the 3’UTR of target mRNAs, resulting in translational
repression [5] or mRNA degradation [6,7], or at the transcriptional level
by interacting with gene promoters to activate or repress gene expres-
sion [8,9]. miRNAs play critical roles in diverse biological and cellular
processes including metabolism, differentiation and apoptosis. The
physiological relevance ofmiRNAhas also been demonstrated by the as-
sociation of aberrant miRNA expression with a large number of human
diseases including cancer, diabetes, neurological disorders, heart failure,
pulmonary hypertension and autoimmune diseases due to dysfunction
of their target genes [2]. Recent evidence demonstrates thatmiRNAs are
regulators of osteogenesis during embryonic bone development as well
as remodeling of adult bone tissue, a process that involves cell prolifer-
ation, differentiation and functional activity of bone cells [2,10]. For ex-
ample, miRNA (miR)-138 has been demonstrated by our group to
regulate osteoblast differentiation in vitro and in vivo [11], and a novelaboratory (KMEB), Department
arken 25.1, DK-5000 Odense C,panel of miRNAs (OstemiR) were identiﬁed to target osteoblast
differentiation-, stemness-, epigenetics-, and cell cycle-related
genes [12].
Human bonemarrow-derived stromal stem cells (hMSC, also known
as skeletal stem cells and bone marrow mesenchymal stem cells) are a
group of clonogenic and multipotent cells capable of differentiation
into mesoderm-type cells, e.g. osteoblast, adipocyte and chondrocyte
[13]. Alterations in the balance between osteoblast and adipocyte differ-
entiation ofMSC can lead to alterations in bonemass [14].We have pre-
viously reported that high bone mass patients harboring the activating
T253I mutation in Wnt coreceptor low-density lipoprotein receptor-
related protein 5 exhibit increased bonemass and decreased bonemar-
row adipose tissue mass in iliac crest bone biopsies [15]. Additionally,
we have demonstrated that this phenotype was caused by enhanced
differentiation of hMSC by Wnt signaling into the osteoblastic, but not
adipocytic, fate [15].
Several miRNAs have been reported to target Wnt inhibitors and
thus activateWnt signaling and bone formation.miR-29 promotes oste-
oblast differentiation through activation of Wnt signaling by a positive
feedback loop,wheremiR-29 can be activated byWnt signaling and tar-
gets Wnt inhibitors CTNNBIP1, DKK1, SFRP2 and Kremen2 [16–18].
miR-27 andmiR-335 activateWnt signaling and further stimulate oste-
oblast differentiation by targetingWnt inhibitors APC and DKK1 respec-
tively [19,20].
However, howWnt signaling regulates the expression of miRNAs in
hMSC is poorly characterized. In this study, we analyzed the expression
of 88 miRNAs upon Wnt3a stimulation of hMSC by miRNA PCR array.
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hMSC proliferation and osteoblast differentiation.
2. Material and methods
2.1. Cell culture and hMSC differentiation
The culture and differentiation of hMSC as well as preparation of
Wnt3a conditioned medium (Wnt3a) and control conditioned medium
(CCM) have previously been described [15]. For the current experi-
ments we employed a human telomerized bone marrow derived stro-
mal stem cells line: hMSC-TERT that has previously been described
and expresses all markers of primary hMSC including in vivo bone
formation [21,22]. We will refer these cells as hMSC in the manuscript.
Conditioned media containing Wnt3a were prepared from murine
L-cell overexpressingWnt3a (ATCC, CRL-2647) and CCMwere prepared
from control L cell line (ATCC, CRL-2648). Cell culture and preparation
of the conditioned media were performed as described by ATCC.
Mouse bone marrow-derived stromal cell line ST2 was maintained
in RPMI-1640 (Invitrogen) containing 10% fetal bovine serum (FBS,
Sigma) and 100 μg/ml streptomycin/penicillin (Invitrogen). HEK293T
and MDA-MB231 human breast carcinoma cells were cultured in
DMEM with 10% FBS and 100 μg/ml streptomycin/penicillin.
2.2. miRNA PCR array and miScript primer assay
hMSC were seeded in 6 cm dishes and treated with 20% Wnt3a or
CCM for 24 hours. Total RNAs including miRNAs were isolated byA
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Fig. 1. The expression of miR-141-3p is inhibited by Wnt signaling. (A–B) hMSC were trea
for 24 hours, and the expression of miRNAs was analyzed by human miFinder miRNA PCR a
assay. Data are shown asmean+ S.D., n= 5, * P b 0.05 (B). (C)Wnt reporter cell linewas reve
with 20% CCMorWnt3a for 24 hours. The luciferase activitywasmeasured by dual luciferase ass
above, followed by treatment with 20% Wnt3a for 7 days. ALP activity was normalized against
transfected by 9 nM miR-141-3p as above, and mature miR-141-3p was quantitated by miS
mean + S.D., n = 3, ** P b 0.005.miRNeasy mini kit (Qiagen), reverse transcribed by miScript II RT kit
(Qiagen), andmaturemiRNAswere quantitated bymiScript PCR system
(Qiagen). Human miFinder miRNA PCR array (Qiagen) was performed
on StepOnePlus real-time PCR system (Applied Biosystems) according
to themanufacturer's instruction. To analyze the expression of a speciﬁc
mature miRNA, miScript primer assay was performed. Universal primers
for selected mature miRNAs were purchased from Qiagen, and their
expression was analyzed by miScript PCR system.
2.3. Cell transfection
hMSC was reverse transfected with miRNA or siRNA by Lipofecta-
mine™ 2000 (Invitrogen). Brieﬂy, 1 pmol miRNA (Qiagen) or 5 pmol
siRNA (Ambion) was mixed with 1 μl or 0.25 μl Lipofectamine 2000 in
10 ul or 50 ul serum free medium for 20 minutes at room temperature
in 96-well plate. The cells were seeded at 6 × 103/cm2 or to be ap-
proximately 70% conﬂuent on the next day. The ﬁnal concentration
of miRNA and siRNA was 9 nM or 33 nM in a 96-well plate, these
concentrations were also applied to other culture formats. The
transfection efﬁciency of miR-141-3p was determined by miScript
PCR system. To transfect miScript target protector, 225 nM ﬁnal con-
centration was used.
2.4. Cell viability and cell cycle analysis
Cell viability was determined by CellTiter Blue reagent (Promega) as
described previously [23]. For cell cycle analysis, hMSCwere transfected
with miRNA or siRNA in 6 cm dishes. After 24 hours, the cells wereiR-ctrl miR-141-3p
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rray (A). The downregulation of miR-141-3p was further conﬁrmed by miScript primer
rse transfectedwith 9 nM control miRNA (miR-ctrl) or miR-141-3p followed by treatment
ay and presented asmean+ S.D., n=5, ** P b 0.005. (D) hMSCwas reverse transfected, as
cell number. Data are shown as mean + S.D., n = 8, ** P b 0.005. (E) hMSC was reverse
cirpt primer assay. Nontransfected hMSC was used as control (Ctrl). Data are shown as
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order to arrest the cells in G2/M phase. The cells were subsequently
trypsinized and washed with ice-cold PBS. 5 × 105 cells were ﬁxed in
70% ice-cold ethanol at−20 °C for at least two hours and followed by
treatment with 250 μl PBS containing 10 μg/ml RNase A and 20 μg/ml
propidium iodide (PI) for 20 minutes. FACS analysis was performed
on Cell Lab Quanta SC™ ﬂow cytometer (Beckman Coulter), and data
was analyzed by Kaluza software.
2.5. Cell apoptosis assay
For cell apoptosis assay, hMSC were transfected with miRNA in
10 cm dishes. Cells were collected after 48 hours, re-suspended in cul-
ture medium to 5 × 106/ml, stained with 40 nM MitoTracker® Red
CMXRos (Invitrogen) for 30 min at cell culture condition for mitochon-
dria activity. Then cells were washed by PBS, resuspended in PBS at
106/ml and stained with 100 nM YO-PRO®-1 (Invitrogen) on ice for
20 min for cellmembranepermeability. In addition, apoptotic cellmarker
Caspase 3 was examined by Western blot analysis 48 hours following
transfection.
2.6. Real-time qRT-PCR
hMSC differentiation marker expressions were determined by
real-time qRT-PCR as described previously [15,23,24]. To determine
the miR-141-3p effects on the expression on target genes, hMSC were
transfected with miR-141-3p or control and gene expression was
analyzed after 48 hours. Primers used in this study are: cell divisionDC
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Fig. 2.miR-141-3p inhibits hMSC proliferation. (A) hMSCwas reverse transfected with 9nM co
3p. Cell number was analyzed by CellTiter Blue assay (Left) or hemacytometer (Right) after
transfected as above, and cell number was analyzed by CellTiter Blue assay from day 1 to day
with 0–13.3 nM miR-ctrl or miR-141-3p. Cell number was analyzed as above after 48 hours.
and cell number was analyzed as above. Data are shown as mean + S.D., n = 8. **P b 0.005.cycle 25A (CDC25A) forward primer 5’-GATCTCAAGAGGAGTCTCCACC-
3’ and reverse primer 5’-TAAATCCTGATGTTTCCCAGC-3’; cyclin D1
(CCND1) forward primer 5’-AGCTGCTGCAAATGGAGC-3’ and reverse
primer 5’-GGGTCACACTTGATCACTCTGG-3’. GAPDH was used as internal
control.
2.7. Alkaline phosphatase (ALP) activity assay and alizarin red S staining
ALP activity was quantitated as described [23]. For alizarin red S stain-
ing, cells were cultured in osteoblast induction medium for 12 days,
washed with PBS, ﬁxed with ice-cold 70% ethanol for 30 minutes and
stained with 40 mM alizarin red S (pH 4.2) for 1 hour.
2.8. Immunoprecipitation and Western blot analysis
Cell were lysed in RIPA buffer (Sigma) containing 1 mM PMSF and
2mMvanadate, and protein concentrationwasmeasured by Coomassie
Plus® protein assay reagent (Pierce). A 600 ug protein was mixed with
50 ul Protein G-Agarose (Roche), incubated at 4 °C for 3 hours and cen-
trifuged at 1000 g, 4 °C for 30 seconds. The supernatant was incubated
with 2 ug rabbit anti-CDK2 antibody (sc-163, Santa Cruz) at 4 °C for
2 hours. A 50 ul Protein G-Agarose was added, and the mixture was
incubated overnight. Immunoprecipitates were collected by centrifuga-
tion and washed in RIPA buffer for four times. The pellets were re-
suspended in 40 μl NuPAGE® LDS sample buffer, boiled at 95 °C for
10 minutes and the supernatants collected for electrophoresis.Western
blot analysis was performed on NuPAGE® SDS-PAGE gel system
(Invitrogen) according to manufacturer's instruction. Antibodies used2500
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48 hours. Data are shown as mean + S.D., n = 6–8, **P b 0.005. (B) hMSC was reverse
9. Data are shown as mean ± S.D., n = 6, **P b 0.005. (C) hMSC was reverse transfected
Data are shown as mean ± S.D., n = 7, **P b 0.005. (D) hMSC was reverse transfected,
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Santa Cruz), rabbit anti-CCNE2 (1:200, sc-22777, Santa Cruz), rabbit
anti-CycD1 (1:200, sc-718, Santa Cruz), rabbit anti-Caspase-3 (1:1000,
Cell Signaling), rabbit anti-CDK2 (1:1000, sc-163, Santa Cruz) and
mouse anti-phosphotyrosine (1:2000, 05-321, Upstate). Mouse anti-
α-tubulin (1:1000, T-5168, Sigma) was used as control.2.9. 3’UTR-reporter assay
Luciferase reporter vector containing 3’UTR of human CDC25A was
purchased from CD BioSciences Inc, USA. Mutations in miR-141-3p
targeting site in 3’UTR of CDC25A (Fig. 4A) was introduced by using
QuikChange Lightning Multi Site-Directed Mutagenesis Kit (Agilent
Technologies) as instructed. HEK293T cells were reverse transfected
by100ng reporter vector togetherwith 13.3 nMmiR-141-3p. Luciferase
activity was measured by luciferase assay system (Promega) and
normalized against protein concentration quantitated by Coomassie
plus protein assay reagent (Pierce).2.10. Bioinformatic and statistical analysis
To predicate the interaction between miR-141-3p and genes in-
volved in cell cycle control, we ﬁrst curated cell cycle genes expressed
at basal level in our hMSC cells [22]. These genes were screened for
miR-141-3p target sites by using Web tools: microRNA.org [25] and
conﬁrmed by using Pictar [26] and TargetScan [27]. The targeting sites
of miR-141-3p in Wnt components were predicated as above, and
known gene targets of miR-141-3p were retrieved from TarBase [28].
Differences between groups were examined using Student's t-test,
and P b 0.05 was considered signiﬁcant.A
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Fig. 3.miR-141-3p arrests hMSC at G1 phase. (A–B) hMSC was reverse transfected with 9 nM
0.1 ug/mlNocodazole for 30 hours, and then cellswere stained by propidium iodide for FACS ana
*P b 0.05, **P b 0.005. (C-D)miR-141-3p does not induce cell apoptosis. hMSCwas reverse trans
YO-PRO-1 for FACS (C), or cell were collected for Western blot analysis of Caspase-3 (D).3. Results
3.1. miR-141-3p is down-regulated by canonical Wnt signaling
We have previously demonstrated that canonical Wnt signaling
determines hMSC differentiation into osteoblast or adipocyte lineages
and this was associated with activation of a novel Wnt target gene:
TNFRSF19 as well as the non-canonical Wnt/JNK pathway [15,23,24].
Here, we examined the hypothesis that Wnt signaling mediates its reg-
ulatory effects on hMSC through regulation of miRNAs. We compared
the expression of 88 miRNAs in hMSC following Wnt3a stimulation by
miFinder®miRNA PCR array. We observed that the levels of miRNAs:
miR-142-3p, miR-144-3p and miR-302c-3p were increased and the
levels of miR-141-3p were decreased (Fig. 1A). The inhibitory effect of
Wnt3a onmiR-141-3p expressionwas further conﬁrmed in an indepen-
dentmiScript primer assay (Fig. 1B). To determinewhethermiR-141-3p
affects Wnt signaling, we transfected a Wnt reporter cell line, estab-
lished by stable infection of hMSC with lentivirus expressing TCF/LEF-
Luc reporter (CLS-018 L, SABiosciences) as well as Renilla luciferase
gene (GenTarget Inc.) as control, with miR-141-3p. Subsequently, the
cells were treated with Wnt3a or CCM for 24 hours. As seen in Fig. 1C,
overexpressing miR-141-3p strongly inhibited Wnt3a-induced lucifer-
ase activity. In addition, miR-141-3p inhibited Wnt3a-induced ALP
activity (Fig. 1D). The transfection efﬁciency of miR-141-3p was con-
ﬁrmed by miScript primer assay (Fig. 1E).
3.2. miR-141-3p inhibits hMSC proliferation by arresting hMSC at G1
As seen in Fig. 2A, miR-141-3p signiﬁcantly decreased cell prolifera-
tion 48 hours following transfection and anti-miR-141-3p increased cell
proliferation. Signiﬁcant inhibition of miR-141-3p on cell proliferation
was observed during 9 days of culture (Fig. 2B) and was mediatedorescence
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control miRNA (miR-ctrl) or miR-141-3p. The next day cells were treated with or without
lysis (A). Percentage of cells inG1/G0, G2/M, S and subG1phasewere calculated (B). n=3,
fected as above. After 48 hours, cells were double stained byMitoTracker Red CMXRos and
2118 W. Qiu, M. Kassem / Biochimica et Biophysica Acta 1843 (2014) 2114–2121by concentrations of miRNA, used in transfection, as low as 1.7 nM
(P b 0.005) (Fig. 2C). The inhibitory effect of miR-141-3p on cell
proliferation was further conﬁrmed in other cell models: primary
human adipose tissue derived MSC, primary bone marrow derived
MSC (Supplementary Fig. S1A and B) and mouse stromal stem cell
line ST2 cells (P b 0.005). The effects on cell proliferation were less
pronounced in HEK 293 T cells (P = 0.035) and was absent in the
MDA-MB231 breast cancer line (Supplementary Fig. S1C). We also
examined the effect of miR-141-5p, which is processed from the
same stem loop structure, and miR-200a-3p, which belongs to the
same miRNA precursor family associated with cell proliferation. All
the three miRNAs inhibited cell proliferation, and miR-141-3p exhibited
the strongest inhibitory effects (Fig. 2D).
To determine the cellular mechanisms of the inhibitory effects on
cell proliferation, we examined the effects of miR-141-3p on cell cycle.
Overexpression of miR-141-3p increased cells at G1/G0 from 65% to
78%, and correspondingly cells at G2/M decreased from 17% to 8%, and
S phase cells decreased from 14% to 11% (Fig. 3A-B). Following
30 hours of treatment with 0.1 μg/ml Nocodazole, known to arrest
cells at G2/M, FACS analysis revealed that 46% cells transfected with
control miRNA (miR-ctrl) were arrested at G2/M and 36% cells were atmiR-ctrl miR-141-3p
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by real-time qRT-PCR and normalized against GAPDH (n= 5), **P b 0.005 (B). The protein leve
α-tubulin was used as internal control. The semi-quantitation of the expression of CDC25A wa
transfected with miR.ctrl was set to 1. n = 3, *P b 0.05 (C). (D) hMSC was reverse transfected
was used for immunoprecipitation (IP) by anti-CDK2 antibody or IgG as control and then imm
cells were reverse transfected with 100 ngwild type CDC25A 3’UTR reporter (3’UTR-CDC25A) o
normalized by protein concentration and presented as mean+ S.D., n= 8. **P b 0.005. (F) hMS
target protector control or miScript CDC25A protector for 48 hours. Cell number was analyzedG1/G0 and S phase. Conversely, 75% of the cells transfected with
miR-141-3p remained at G1/G0 phase, which was similar to miR-141-
3p transfected cells without Nocodazole treatment (Fig. 3A–B).
We also examined the effects of miR-141-3p on cell apoptosis by
staining cells with MitoTracker Red CMXRos for mitochondria activity
and YO-PRO-1 for cell permeability, which is known to be affected in
apoptotic cells. FACS analysis did not demonstrate the presence of apo-
ptotic YO-PRO-1 positive cells with reduced MitoTracker Red CMXRos
signal (Fig. 3C). Additionally, Western blot analysis of Caspase-3 did
not detect the apoptosis associated 17 kDa cleaved fragment (Fig. 3D).
Thus, miR-141-3p inhibited hMSC proliferation by arresting cells in G1
phase without exerting effects on cell apoptosis.
3.3. CDC25A is miR-141-3p target gene
To explore how miR-141-3p arrests hMSC in G1 phase, we ﬁrst
curated 140 cell cycle related genes expressed in our hMSC cell line
from a previous microarray study [22]. Among them, 18 genes were
found to have at least one targeting site of miR-141-3p as evidenced
from micorRNA.org resources (Supplemental Table 1). The miR-141-
3p targeting site in the CDC25A gene was also conﬁrmed by TargetScanCCND1
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s analyzed by ImageJ software and normalized against α-tubulin. The expression in cells
as above, and proteins were collected 72 hours upon transfection. A 600 ng total protein
unoblotted (IB) with anti-CDK2 antibody or anti-phosphotyrosine (pTyr). (E) HEK293T
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decreased CDC25A protein levels (Fig. 4C) but surprisingly increased
its expression at the mRNA level (Fig. 4B). CDC25A is a phosphatase
which activates the CDK2-cyclin E and CDK2-cyclin A complexes
during G1-S transition by removing inhibitory phosphate groups
from threonine-14 and tyrosine-15 of CDK2 [29]. Western blot anal-
ysis revealed that CDK2 was not affected by miR-141-3p (Fig. 4C).
Further, CDK2 was immunoprecipitated from cells transfected with
either miR-ctrl or miR-141-3p and probed for its phosphotyrosine
level by anti-phosphotyrosine antibody. Consistent with decreased
CDC25A protein levels by miR-141-3p, the phosphotyrosine level
was higher in cells transfected with miR-141-3p (Fig. 4D). To con-
ﬁrm that CDC25A was a direct target of miR-141-3p, we employed a
CDC25A 3’UTR luciferase reporter assay. Mutagenesis of miR-141-3p
targeting site in CDC25A 3’UTR abolished the inhibitory effect of miR-
141-3p (Fig. 4A, E). Furthermore, transfection of hMSC with miScript
CDC25Aprotector rescued the inhibitory effect ofmiR-141-3p on cell pro-
liferation (Fig. 4F).
Cyclin E2 (CCNE2) and E2F transcription factor 3 (E2F3) are also in-
volved in G1/S transition and were predicated to have miR-141-3p
targeting sites by miRNA.org, TargetScan and PicTar (Supplemental
Table 1). However,Western blot analysis did not reveal reduced expres-
sion of these proteins following miR-141-3p overexpression (Fig. 4C).
As a known target of miR-141-3p and in G1/S transition regulator,
CCND1 is upregulated by miR-141-3p [30], which was also conﬁrmed
in our study (Fig. 4C). These data suggested that reduced CDC25A may
be responsible for G1 arrest.A
0
0.001
0.002
0.003
0.004
0.005
0.006
siCtrl siCDC25A
Re
la
v
e 
ex
pr
es
sio
n
le
ve
l
FL2 Fluor
Co
un
t
C
G1/G0: 46.62%
S: 7.35%
G2/M: 38.64
siCtrl+Nocodazole
**
Fig. 5. Knock down CDC25A inhibits cell proliferation without G1 arrest. hMSC were reverse t
48 hours. (A) The expression of CDC25A was analyzed by real-time qRT-PCR and normalized
analyzed by CellTiter Blue assay after 48 hours. Data are shown as mean + S.D., n = 8, **P b
then cells were stained by propidium iodide for FACS analysis. Data were shown as one of thre3.4. Knock down of CDC25A inhibits cell proliferationwithout signiﬁcant G1
arrest
To further explore the function of CDC25A in inhibition of cell prolif-
eration by miR-141-3p, we employed siRNA-based knock down of
CDC25A. siCDC25A dramatically decreased the expression of basal
CDC25A for more than 90% (Fig. 5A) and inhibited cell proliferation
48 hours after transfection (Fig. 5B). Cell cycle analysis by PI staining
and FACS analysis did not demonstrate G1/G0 arrest by siCDC25A
(Fig. 5C). These results suggested that CDC25A is a potential mediator
of miR-141-3p inhibitory effects on cell proliferation.
3.5. miR-141-3p inhibits in vitro osteoblast differentiation of hMSC
We investigated the effect of miR-141-3p on in vitro osteoblast dif-
ferentiation of hMSC. The expression of osteoblastic marker genes:
ALP and collagen, type I, alpha 1 (COL1A1) as well as ALP enzyme
activity were signiﬁcantly reduced bymiR-141-3p during 7 days osteo-
blast differentiation (Fig. 6A–B). The expression of runt-related tran-
scription factor 2 (RUNX2) was increased by miR-141-3p at basal level
(P b 0.005), unchanged during 4 days osteoblast differentiation but
signiﬁcantly decreased compared to cells transfected with miR-ctrl
(Fig. 6A). In addition, miR-141-3p impaired in vitro mineralization as
visualized by alizarin red staining (Fig. 6C).
To test for CDC25A as amediator of the inhibitory effect of miR-141-
3p on osteoblast differentiation, we knocked down CDC25A during
in vitro osteoblast differentiation. CDC25A was reduced more than0
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2120 W. Qiu, M. Kassem / Biochimica et Biophysica Acta 1843 (2014) 2114–212150% during 7 days osteoblast differentiation (Fig. 6D).We observed that
siCDC25A inhibited the expression of RUNX2 and COL1A1, but did not
change the expression of ALP (Fig. 6D). These results suggested that
miR-141-3p inhibited in vitro osteoblast differentiation of hMSC
through CDC25A.
4. Discussion
An expanding body of evidence demonstrates that osteoblast differ-
entiation, osteoblast function and bone formation are controlled by
miRNAs [2,10]. In the present study, we identiﬁed miR-141-3p as a
novel Wnt signaling target, which exerts inhibitory effects on Wnt
signaling. We also observed that part of the inhibitory effects of miR-
141-3ponhMSCproliferation anddifferentiation ismediated by targeting
CDC25A.
miR-141-3p belongs to the miR-200 family which consists of ﬁve
miRNAs arranged into two clusters (miRs-200b/a/429 and miRs-
200c/141) on chromosome 1 and 12 in humans [31]. miR-141 shares
an identical seed sequence and differs by only one nucleotide with
miR-200a [32]. Previous studies have shown that miR-141/miR-
200 are involved in cancer development and metastasis. miR-141/
mirR-200a are associated with ovarian tumorigenesis through targeting
p38α and controlling oxidative stress response [5]. miR-141 targets
PTEN, BRD3 and UBAP1, which affect AKT, Rb/E2F signaling and cell pro-
liferation, respectively, in nasopharyngeal carcinoma [30]. The miR-200
family inhibits epithelial–mesenchymal transition, which is an essential
initial step of cancer metastasis, by targeting E-cadherin, ZEB1 and ZEB2C
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Fig. 6.miR-141 inhibits in vitro osteoblast differentiation of hMSC. (A–C) hMSC was reverse
medium (NM) or osteogenic induction medium (OIM) for 4–13 days. The expression o
GAPDH. Data are shown as mean + S.D., n = 6, **P b 0.005 comparing to miR-ctrl plus
Data are shown as mean + S.D., n = 8. **P b 0.005 (B). In vitro mineralization was determined b
siRNA (siCtrl) or siRNA targeting CDC25A (siCDC25A) followed by osteoblast differentiation f
normalized against GAPDH. Data are shown as mean + S.D., n = 6. *P b 0.05, **P b 0.005.[31]. Conversely, miR-200 has been reported to promote cancer metasta-
sis capacity of amousebreast cancer cell line as it enhancedmesenchymal
to epithelial cell transition by targeting mouse Zeb2 [33]. Furthermore,
miR-141/miR-200 family has been reported to inhibit cell proliferation
in cancer cells [34,35]. However, in nasopharyngeal carcinoma cells, inhi-
bition of miR-141 reduced cell viability and increased cell apoptosis [30].
In our study, we observed that miR-141-3p inhibited hMSC proliferation
by arresting the cells at G1 phase without detectable effects on cell apo-
ptosis. Both miR-141-3p and miR-200a-3p inhibited hMSC proliferation
but miR-141-3p exhibited much stronger effects (Fig. 2D), suggesting
that minor differences in nucleotide sequence existing between miR-
141-3p and miR-200a-3p are relevant for their function.
We observed that miR-141-3p increased the expression of CDC25A
in themRNA level and decreased its expression in the protein level, sug-
gesting that miR-141-3p affects gene expression on both a transcrip-
tional and posttranscriptional level. miR141/miR-200a have also been
reported to affect different aspects of bone biology. For example,
miR141/miR-200a have been reported to inhibit BMP induced osteo-
blast differentiation in the mouse pre-osteoblastic MC3T3-E1 cell line
by inhibiting osteoblastic transcription factor Dlx5 [36]. Additionally,
elevated miR-141 levels were observed in serum from patients with
prostate cancer and bone-metastasis, and serum levels of miR-141
were associated with the presence of increased bone lesions and were
correlated with serum ALP activity [7]. In our study, miR-141-3p signif-
icantly reduced the expression of early osteoblast differentiation
markers, including ALP, COL1A1 and RUNX2. Knocking down CDC25A
inhibited hMSC proliferation and osteoblast differentiation, but this0
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transfected with 9 nM control miRNA (miR-ctrl) or miR-141-3p and cultured in normal
f osteoblastic markers was analyzed by real-time qRT-PCR and normalized against
OIM (A). ALP activity was quantitated at day 7 and normalized against cell number.
y alizarin red staining on day 13 (C). (D) hMSC were reverse transfected with 33 nM control
or 7 days. The expression of osteoblastic markers was analyzed by real-time qRT-PCR and
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sibly due the functional rescue by CDC25B or CDC25C [29]. This notion is
supported by evidence that biological effects of CDC25A deﬁciency was
rescued by CDC25B in adult mice deﬁcient in the CDC25A gene [37,38].
It is plausible that there exist other proteins that are targeted
by miR-141-3p and mediate its effect on hMSC proliferation and differ-
entiation. We observed that miR-141-3p inhibited Wnt signaling and
Wnt3a induced ALP activity. Searching TarBase [28] for known targets
of miR-141-3p, we identiﬁed Wnt target gene CCND1 [30] as the only
miR-141-3p target involved in Wnt signaling. Upregulation of CCND1
by miR-141-3p could not explain the miR-141 inhibitory effect on
Wnt signaling. By screeningmiR-141-3p targeting sites inWnt signaling
genes (http://www.stanford.edu/group/nusselab/cgi-bin/wnt/) using
the microRNA.org web resource [25], ﬁve Wnt genes: WNT5A,
WNT16, FZD8, APC2 and AXIN1 were predicated to have one miR-
141-3p target site (Supplemental Table 2). WNT16, APC2 and
AXIN1 are not expressed in hMSC [15]. For FZD8, no miR-141-3p
targeting site was detected by two additional predication tools
(TargetScan and PicTar). The same targeting site of miR-141-3p in
WNT5A was also predicated by TargetScan, but this Wnt ligand
was normally regarded as noncanonical Wnt ligand. Thus, bioinformatics
analysis did not provide insight into howmiR-141-3p inhibited Wnt sig-
naling. Whether miR-141-3p inhibits Wnt signaling directly or indirectly
needs to be explored.
In summary, our results provide new insight into the interaction of
Wnt signaling and miRNAs in hMSC proliferation and differentiation.
As a regulator of hMSC proliferation and differentiation, targeting
miR-141-3p could be a novel anabolic therapy for bone loss diseases,
e.g. osteoporosis.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.bbamcr.2014.06.004.
Acknowledgement
We thank Linda Harkness for proof reading. This work was supported
by grants from Fabrikant Vilhelm Pedersen og Hustrus, Novo Nordisk
Foundation, a local grant from Odense University Hospital.
References
[1] L. He, G.J. Hannon, MicroRNAs: small RNAs with a big role in gene regulation, Nat.
Rev. Genet. 5 (2004) 522–531.
[2] H. Taipaleenmaki, L. Bjerre Hokland, L. Chen, S. Kauppinen, M. Kassem, Mechanisms
in endocrinology: micro-RNAs: targets for enhancing osteoblast differentiation and
bone formation, Eur. J. Endocrinol. 166 (2012) 359–371.
[3] L.P. Lim, N.C. Lau, P. Garrett-Engele, A. Grimson, J.M. Schelter, J. Castle, D.P. Bartel,
P.S. Linsley, J.M. Johnson, Microarray analysis shows that some microRNAs down-
regulate large numbers of target mRNAs, Nature 433 (2005) 769–773.
[4] A. Kozomara, S. Grifﬁths-Jones, miRBase: integrating microRNA annotation and
deep-sequencing data, Nucleic Acids Res. 39 (2011) D152–D157.
[5] P.H. Olsen, V. Ambros, The lin-4 regulatory RNA controls developmental timing in
Caenorhabditis elegans by blocking LIN-14 protein synthesis after the initiation of
translation, Dev. Biol. 216 (1999) 671–680.
[6] G. Hutvagner, P.D. Zamore, A microRNA in a multiple-turnover RNAi enzyme com-
plex, Science 297 (2002) 2056–2060.
[7] C. Llave, Z. Xie, K.D. Kasschau, J.C. Carrington, Cleavage of Scarecrow-like mRNA tar-
gets directed by a class of Arabidopsis miRNA, Science 297 (2002) 2053–2056.
[8] B.A. Janowski, S.T. Younger, D.B. Hardy, R. Ram, K.E. Huffman, D.R. Corey, Activating
gene expression in mammalian cells with promoter-targeted duplex RNAs, Nat.
Chem. Biol. 3 (2007) 166–173.
[9] B. Khraiwesh, M.A. Arif, G.I. Seumel, S. Ossowski, D. Weigel, R. Reski, W. Frank, Tran-
scriptional control of gene expression by microRNAs, Cell 140 (2010) 111–122.
[10] J.B. Lian, G.S. Stein, A.J. van Wijnen, J.L. Stein, M.Q. Hassan, T. Gaur, Y. Zhang,
MicroRNA control of bone formation and homeostasis, Nat. Rev. Endocrinol. 8
(2012) 212–227.
[11] T. Eskildsen,H. Taipaleenmaki, J. Stenvang, B.M.Abdallah,N.Ditzel, A.Y.Nossent,M. Bak,
S. Kauppinen,M. Kassem,MicroRNA-138 regulates osteogenic differentiation of human
stromal (mesenchymal) stem cells in vivo, Proc. Natl. Acad. Sci. U. S. A. 108 (2011)
6139–6144.[12] T. Eguchi, K. Watanabe, E.S. Hara, M. Ono, T. Kuboki, S.K. Calderwood, OstemiR:
a novel panel of microRNA biomarkers in osteoblastic and osteocytic differentiation
from mesencymal stem cells, PLoS One 8 (2013) e58796.
[13] B.M. Abdallah, M. Kassem, Human mesenchymal stem cells: from basic biology to
clinical applications, Gene Ther. 15 (2008) 109–116.
[14] J.M. Gimble, S. Zvonic, Z.E. Floyd, M. Kassem, M.E. Nuttall, Playing with bone and fat,
J. Cell. Biochem. 98 (2006) 251–266.
[15] W. Qiu, T.E. Andersen, J. Bollerslev, S. Mandrup, B.M. Abdallah, M. Kassem, Patients
with high bone mass phenotype exhibit enhanced osteoblast differentiation and in-
hibition of adipogenesis of human mesenchymal stem cells, J. Bone Miner. Res. 22
(2007) 1720–1731.
[16] K. Kapinas, C.B. Kessler, A.M. Delany, miR-29 suppression of osteonectin in osteo-
blasts: regulation during differentiation and by canonical Wnt signaling, J. Cell.
Biochem. 108 (2009) 216–224.
[17] Z. Li, M.Q. Hassan, M. Jafferji, R.I. Aqeilan, R. Garzon, C.M. Croce, A.J. van Wijnen, J.L.
Stein, G.S. Stein, J.B. Lian, Biological functions of miR-29b contribute to positive
regulation of osteoblast differentiation, J. Biol. Chem. 284 (2009) 15676–15684.
[18] K. Kapinas, C. Kessler, T. Ricks, G. Gronowicz, A.M. Delany, miR-29 modulates Wnt
signaling in human osteoblasts through a positive feedback loop, J. Biol. Chem.
285 (2010) 25221–25231.
[19] T. Wang, Z. Xu, miR-27 promotes osteoblast differentiation by modulating Wnt sig-
naling, Biochem. Biophys. Res. Commun. 402 (2010) 186–189.
[20] J. Zhang, Q. Tu, L.F. Bonewald, X. He, G. Stein, J. Lian, J. Chen, Effects of miR-335-5p in
modulating osteogenic differentiation by speciﬁcally downregulating Wnt antago-
nist DKK1, J. Bone Miner. Res. 26 (2011) 1953–1963.
[21] J.L. Simonsen, C. Rosada, N. Serakinci, J. Justesen, K. Stenderup, S.I. Rattan, T.G.
Jensen, M. Kassem, Telomerase expression extends the proliferative life-span and
maintains the osteogenic potential of human bone marrow stromal cells, Nat.
Biotechnol. 20 (2002) 592–596.
[22] M. Al-Nbaheen, R. Vishnubalaji, D. Ali, A. Bouslimi, F. Al-Jassir, M. Megges, A.
Prigione, J. Adjaye, M. Kassem, A. Aldahmash, Human stromal (mesenchymal)
stem cells from bone marrow, adipose tissue and skin exhibit differences in molec-
ular phenotype and differentiation potential, Stem Cell Rev. 9 (2013) 32–43.
[23] W. Qiu, Y. Hu, T.E. Andersen, A. Jafari, N. Li, W. Chen, M. Kassem, Tumor necrosis
factor receptor superfamily member 19 (TNFRSF19) regulates differentiation fate
of human mesenchymal (stromal) stem cells through canonical Wnt signaling and
C/EBP, J. Biol. Chem. 285 (2010) 14438–14449.
[24] W. Qiu, L. Chen, M. Kassem, Activation of non-canonical Wnt/JNK pathway by
Wnt3a is associated with differentiation fate determination of human bonemarrow
stromal (mesenchymal) stem cells, Biochem. Biophys. Res. Commun. 413 (2011)
98–104.
[25] D. Betel, M. Wilson, A. Gabow, D.S. Marks, C. Sander, The microRNA.org resource:
targets and expression, Nucleic Acids Res. 36 (2008) D149–D153.
[26] A. Krek, D. Grun, M.N. Poy, R. Wolf, L. Rosenberg, E.J. Epstein, P. MacMenamin, I. da
Piedade, K.C. Gunsalus, M. Stoffel, N. Rajewsky, Combinatorial microRNA target
predictions, Nat. Genet. 37 (2005) 495–500.
[27] B.P. Lewis, C.B. Burge, D.P. Bartel, Conserved seed pairing, often ﬂanked by adeno-
sines, indicates that thousands of human genes are microRNA targets, Cell 120
(2005) 15–20.
[28] T. Vergoulis, I.S. Vlachos, P. Alexiou, G. Georgakilas, M. Maragkakis, M. Reczko, S.
Gerangelos, N. Koziris, T. Dalamagas, A.G. Hatzigeorgiou, TarBase 6.0: capturing
the exponential growth of miRNA targets with experimental support, Nucleic
Acids Res. 40 (2012) D222–D229.
[29] R. Boutros, V. Lobjois, B. Ducommun, CDC25 phosphatases in cancer cells: key
players? Good targets? Nat. Rev. Cancer 7 (2007) 495–507.
[30] L. Zhang, T. Deng, X. Li, H. Liu, H. Zhou, J. Ma, M. Wu, M. Zhou, S. Shen, Z. Niu, W.
Zhang, L. Shi, B. Xiang, J. Lu, L. Wang, D. Li, H. Tang, G. Li, microRNA-141 is involved
in a nasopharyngeal carcinoma-related genes network, Carcinogenesis 31 (2010)
559–566.
[31] M. Korpal, Y. Kang, The emerging role of miR-200 family of microRNAs in epithelial-
mesenchymal transition and cancer metastasis, RNA Biol. 5 (2008) 115–119.
[32] N.E. Renthal, K.C. Williams, C.R. Mendelson, MicroRNAs–mediators of myo-
metrial contractility during pregnancy and labour, Nat. Rev. Endocrinol. 9
(2013) 391–401.
[33] D.M. Dykxhoorn, Y. Wu, H. Xie, F. Yu, A. Lal, F. Petrocca, D. Martinvalet, E. Song, B.
Lim, J. Lieberman, miR-200 enhances mouse breast cancer cell colonization to
form distant metastases, PLoS One 4 (2009) e7181.
[34] Y. Du, Y. Xu, L. Ding, H. Yao, H. Yu, T. Zhou, J. Si, Down-regulation of miR-141 in gastric
cancer and its involvement in cell growth, J. Gastroenterol. 44 (2009) 556–561.
[35] X.Y. Yu, Z. Zhang, J. Liu, B. Zhan, C.Z. Kong, MicroRNA-141 is downregulated in
human renal cell carcinoma and regulates cell survival by targeting CDC25B,
Oncol. Targets Ther. 6 (2013) 349–354.
[36] T. Itoh, Y. Nozawa, Y. Akao, MicroRNA-141 and -200a are involved in bone morphoge-
netic protein-2-induced mouse pre-osteoblast differentiation by targeting distal-less
homeobox 5, J. Biol. Chem. 284 (2009) 19272–19279.
[37] G. Lee, L.S. White, K.E. Hurov, T.S. Stappenbeck, H. Piwnica-Worms, Response of
small intestinal epithelial cells to acute disruption of cell division through CDC25
deletion, Proc. Natl. Acad. Sci. U. S. A. 106 (2009) 4701–4706.
[38] G. Lee, S. Origanti, L.S.White, J. Sun, T.S. Stappenbeck, H. Piwnica-Worms, Contributions
made by CDC25 phosphatases to proliferation of intestinal epithelial stem and progen-
itor cells, PLoS One 6 (2011) e15561.
